Advertisement Foamix Receives US Patent - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Foamix Receives US Patent

Patent covers foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections

Foamix has received US Patent No. 7575739 pertaining to its foam technology. The patent covers foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.

Reportedly, the company has five issued US patents covering its OilGel and topical foam technology platforms till date. An additional 70 US patent applications, protecting its proprietary foam platforms are under prosecution, covering compositions, applications, methods of use and delivery devices.

Dov Tamarkin, CEO of Foamix, said: The novelty of our foam technology platform is that it enables facile delivery of active agents to the inflicted site. Our foams are breakable – they are easily applied to the sensitive area of wounds and burns and they are absorbed readily into the treated area.